Skip to main content
Erschienen in: International Journal of Hematology 4/2016

21.06.2016 | Original Article

Clinical features, mutations and treatment of 104 patients of Diamond-Blackfan anemia in China: a single-center retrospective study

verfasst von: Yang Wan, Xiaojuan Chen, Wenbin An, Min Ruan, Jingliao Zhang, Lixian Chang, Ranran Zhang, Shuai Zhu, Yingchi Zhang, Wenyu Yang, Ye Guo, Weiping Yuan, Yao Zou, Yumei Chen, Xiaofan Zhu

Erschienen in: International Journal of Hematology | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Diamond-Blackfan anemia (DBA) is an inherited bone marrow failure syndrome characterized by a paucity of erythroid progenitors. We summarized the clinical and genetic features of 104 DBA patients in a single-center retrospective study in China. Data of DBA patients who received consultations at our center from 2003 to 2015 were analyzed retrospectively. Genes encoding 10 ribosomal proteins (RPs) and GATA1 were sequenced for mutation detection. Our cohort was composed of 65 males and 39 females. Congenital malformations were observed in 19 patients. Mutations of the RP genes were detected in 58.3 % patients. Twenty different mutations were first reported. Thirty-four patients received prednisone combined with CsA therapy, and improvement was observed in 20 cases. During follow-up for a median 39 months, 33.7 % of the patients achieved remission, 41.3 % of the patients were persistently transfusion independent, 21.7 % of the patients were transfusion dependent, and three patients died. The patient group with detected mutations had a younger age of disease onset, a higher malformation rate, and tended to have a lower remission rate and a higher transfusion-dependence rate. Prednisone in combination with cyclosporine A can be a second-line choice for DBA patients. Differences were detected between DBA patients with and without detectable mutations in the genes studied.
Literatur
1.
Zurück zum Zitat Vlachos A, Blanc L, Lipton JM. Diamond Blackfan anemia: a model for the translational approach to understanding human disease. Expert Rev Hematol. 2014;7:359–72.CrossRefPubMed Vlachos A, Blanc L, Lipton JM. Diamond Blackfan anemia: a model for the translational approach to understanding human disease. Expert Rev Hematol. 2014;7:359–72.CrossRefPubMed
2.
Zurück zum Zitat Vlachos A, Ball S, Dahl N, Alter BP, Sheth S, Ramenghi U, et al. Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference. Br J Haematol. 2008;142:859–76.CrossRefPubMedPubMedCentral Vlachos A, Ball S, Dahl N, Alter BP, Sheth S, Ramenghi U, et al. Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference. Br J Haematol. 2008;142:859–76.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Ball SE, McGuckin CP, Jenkins G, Gordon-Smith EC. Diamond-Blackfan anaemia in the U.K.: analysis of 80 cases from a 20-year birth cohort. Br J Haematol. 1996;94:645–53.CrossRefPubMed Ball SE, McGuckin CP, Jenkins G, Gordon-Smith EC. Diamond-Blackfan anaemia in the U.K.: analysis of 80 cases from a 20-year birth cohort. Br J Haematol. 1996;94:645–53.CrossRefPubMed
4.
Zurück zum Zitat Willig TN, Niemeyer CM, Leblanc T, Tiemann C, Robert A, Budde J, et al. Identification of new prognosis factors from the clinical and epidemiologic analysis of a registry of 229 Diamond-Blackfan anemia patients. DBA group of Societe d’Hematologie et d’Immunologie Pediatrique (SHIP), Gesellshaft fur Padiatrische Onkologie und Hamatologie (GPOH), and the European Society for Pediatric Hematology and Immunology (ESPHI). Pediatr Res. 1999;46:553–61.CrossRefPubMed Willig TN, Niemeyer CM, Leblanc T, Tiemann C, Robert A, Budde J, et al. Identification of new prognosis factors from the clinical and epidemiologic analysis of a registry of 229 Diamond-Blackfan anemia patients. DBA group of Societe d’Hematologie et d’Immunologie Pediatrique (SHIP), Gesellshaft fur Padiatrische Onkologie und Hamatologie (GPOH), and the European Society for Pediatric Hematology and Immunology (ESPHI). Pediatr Res. 1999;46:553–61.CrossRefPubMed
5.
Zurück zum Zitat Ball S, Orfali K. Molecular diagnosis of Diamond-Blackfan anemia. Methods Mol Med. 2004;91:19–30.PubMed Ball S, Orfali K. Molecular diagnosis of Diamond-Blackfan anemia. Methods Mol Med. 2004;91:19–30.PubMed
6.
Zurück zum Zitat Lipton JM, Atsidaftos E, Zyskind I, Vlachos A. Improving clinical care and elucidating the pathophysiology of Diamond Blackfan anemia: an update from the Diamond Blackfan Anemia Registry. Pediatr Blood Cancer. 2006;46:558–64.CrossRefPubMed Lipton JM, Atsidaftos E, Zyskind I, Vlachos A. Improving clinical care and elucidating the pathophysiology of Diamond Blackfan anemia: an update from the Diamond Blackfan Anemia Registry. Pediatr Blood Cancer. 2006;46:558–64.CrossRefPubMed
8.
Zurück zum Zitat Natalia DPG, Björn A, Monica P, Irma D, Thiébaut N, Sarah B, et al. The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia. Nat Genet. 1999;21:7. Natalia DPG, Björn A, Monica P, Irma D, Thiébaut N, Sarah B, et al. The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia. Nat Genet. 1999;21:7.
9.
Zurück zum Zitat Raiser DM, Narla A, Ebert BL. The emerging importance of ribosomal dysfunction in the pathogenesis of hematologic disorders. Leuk Lymphoma. 2014;55:491–500.CrossRefPubMed Raiser DM, Narla A, Ebert BL. The emerging importance of ribosomal dysfunction in the pathogenesis of hematologic disorders. Leuk Lymphoma. 2014;55:491–500.CrossRefPubMed
10.
Zurück zum Zitat Dutt S, Narla A, Lin K, Mullally A, Abayasekara N, Megerdichian C, et al. Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. Blood. 2011;117:2567–76.CrossRefPubMedPubMedCentral Dutt S, Narla A, Lin K, Mullally A, Abayasekara N, Megerdichian C, et al. Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. Blood. 2011;117:2567–76.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Singh SA, Goldberg TA, Henson AL, Husain-Krautter S, Nihrane A, Blanc L, et al. p53-independent cell cycle and erythroid differentiation defects in murine embryonic stem cells haploinsufficient for Diamond Blackfan Anemia-Proteins: RPS19 versus RPL5. PLoS One. 2014;9:e89098.CrossRefPubMedPubMedCentral Singh SA, Goldberg TA, Henson AL, Husain-Krautter S, Nihrane A, Blanc L, et al. p53-independent cell cycle and erythroid differentiation defects in murine embryonic stem cells haploinsufficient for Diamond Blackfan Anemia-Proteins: RPS19 versus RPL5. PLoS One. 2014;9:e89098.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Vlachos A, Dahl N, Dianzani I, Lipton JM. Clinical utility gene card for: Diamond-Blackfan anemia–update. Eur J Hum Genet. 2013;21(10):1038.CrossRef Vlachos A, Dahl N, Dianzani I, Lipton JM. Clinical utility gene card for: Diamond-Blackfan anemia–update. Eur J Hum Genet. 2013;21(10):1038.CrossRef
13.
Zurück zum Zitat Sankaran VG, Ghazvinian R, Do R, Thiru P, Vergilio JA, Beggs AH, et al. Exome sequencing identifies GATA1 mutations resulting in Diamond-Blackfan anemia. J Clin Investig. 2012;122:2439–43.CrossRefPubMedPubMedCentral Sankaran VG, Ghazvinian R, Do R, Thiru P, Vergilio JA, Beggs AH, et al. Exome sequencing identifies GATA1 mutations resulting in Diamond-Blackfan anemia. J Clin Investig. 2012;122:2439–43.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Parrella S, Aspesi A, Quarello P, Garelli E, Pavesi E, Carando A, et al. Loss of GATA-1 full length as a cause of Diamond-Blackfan anemia phenotype. Pediatr Blood Cancer. 2014;61:1319–21.CrossRefPubMedPubMedCentral Parrella S, Aspesi A, Quarello P, Garelli E, Pavesi E, Carando A, et al. Loss of GATA-1 full length as a cause of Diamond-Blackfan anemia phenotype. Pediatr Blood Cancer. 2014;61:1319–21.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Fagioli F, Quarello P, Zecca M, Lanino E, Corti P, Favre C, et al. Haematopoietic stem cell transplantation for Diamond Blackfan anaemia: a report from the Italian Association of Paediatric Haematology and Oncology Registry. Br J Haematol. 2014;165:673–81.CrossRefPubMed Fagioli F, Quarello P, Zecca M, Lanino E, Corti P, Favre C, et al. Haematopoietic stem cell transplantation for Diamond Blackfan anaemia: a report from the Italian Association of Paediatric Haematology and Oncology Registry. Br J Haematol. 2014;165:673–81.CrossRefPubMed
16.
Zurück zum Zitat El-Beshlawy A, Ibrahim IY, Rizk S, Eid K. Study of 22 Egyptian patients with Diamond-Blackfan anemia, corticosteroids, and cyclosporin therapy results. Pediatrics. 2002;110:e44.CrossRefPubMed El-Beshlawy A, Ibrahim IY, Rizk S, Eid K. Study of 22 Egyptian patients with Diamond-Blackfan anemia, corticosteroids, and cyclosporin therapy results. Pediatrics. 2002;110:e44.CrossRefPubMed
17.
Zurück zum Zitat Alessandri AJ, Rogers PC, Wadsworth LD, Davis JH. Diamond-blackfan anemia and cyclosporine therapy revisited. J Pediatr Hematol Oncol. 2000;22:176–9.CrossRefPubMed Alessandri AJ, Rogers PC, Wadsworth LD, Davis JH. Diamond-blackfan anemia and cyclosporine therapy revisited. J Pediatr Hematol Oncol. 2000;22:176–9.CrossRefPubMed
18.
Zurück zum Zitat Bobey NA, Carcao M, Dror Y, Freedman MH, Dahl N, Woodman RC. Sustained cyclosporine-induced erythropoietic response in identical male twins with Diamond-Blackfan anemia. J Pediatr Hematol Oncol. 2003;25:914–8.CrossRefPubMed Bobey NA, Carcao M, Dror Y, Freedman MH, Dahl N, Woodman RC. Sustained cyclosporine-induced erythropoietic response in identical male twins with Diamond-Blackfan anemia. J Pediatr Hematol Oncol. 2003;25:914–8.CrossRefPubMed
19.
Zurück zum Zitat Ohga S, Mugishima H, Ohara A, Kojima S, Fujisawa K, Yagi K, et al. Diamond-Blackfan anemia in Japan: clinical outcomes of prednisolone therapy and hematopoietic stem cell transplantation. Int J Hematol. 2004;79(1):22–30.CrossRefPubMed Ohga S, Mugishima H, Ohara A, Kojima S, Fujisawa K, Yagi K, et al. Diamond-Blackfan anemia in Japan: clinical outcomes of prednisolone therapy and hematopoietic stem cell transplantation. Int J Hematol. 2004;79(1):22–30.CrossRefPubMed
20.
Zurück zum Zitat Ladomenou F, Gaspar B. How to use immunoglobulin levels in investigating immune deficiencies. Arch Dis Child Educ Pract Ed. 2016. Ladomenou F, Gaspar B. How to use immunoglobulin levels in investigating immune deficiencies. Arch Dis Child Educ Pract Ed. 2016.
21.
Zurück zum Zitat Schmeits PC, Schaap MM, Luijten M, van Someren E, Boorsma A, van Loveren H, et al. Detection of the mechanism of immunotoxicity of cyclosporine A in murine in vitro and in vivo models. Arch Toxicol. 2015;89:2325–37.CrossRefPubMed Schmeits PC, Schaap MM, Luijten M, van Someren E, Boorsma A, van Loveren H, et al. Detection of the mechanism of immunotoxicity of cyclosporine A in murine in vitro and in vivo models. Arch Toxicol. 2015;89:2325–37.CrossRefPubMed
22.
Zurück zum Zitat Seip M, Zanussi GF. Cyclosporine in steroid-resistant Diamond-Blackfan anaemia. Acta Paediatr Scand. 1988;77:464–6.CrossRefPubMed Seip M, Zanussi GF. Cyclosporine in steroid-resistant Diamond-Blackfan anaemia. Acta Paediatr Scand. 1988;77:464–6.CrossRefPubMed
23.
Zurück zum Zitat Leonard EM, Raefsky E, Griffith P, Kimball J, Nienhuis AW, Young NS. Cyclosporine therapy of aplastic anaemia, congenital and acquired red cell aplasia. Br J Haematol. 1989;72:278–84.CrossRefPubMed Leonard EM, Raefsky E, Griffith P, Kimball J, Nienhuis AW, Young NS. Cyclosporine therapy of aplastic anaemia, congenital and acquired red cell aplasia. Br J Haematol. 1989;72:278–84.CrossRefPubMed
24.
Zurück zum Zitat Splain J, Berman BW. Cyclosporin A treatment for Diamond-Blackfan anemia. Am J Hematol. 1992;39:208–11.CrossRefPubMed Splain J, Berman BW. Cyclosporin A treatment for Diamond-Blackfan anemia. Am J Hematol. 1992;39:208–11.CrossRefPubMed
25.
Zurück zum Zitat Naithani R, Chandra J, Narayan S, Singh V, Dutta AK. Diamond-Blackfan anemia: clinical features and treatment results in 4 cases. Hematology. 2006;11:193–5.CrossRefPubMed Naithani R, Chandra J, Narayan S, Singh V, Dutta AK. Diamond-Blackfan anemia: clinical features and treatment results in 4 cases. Hematology. 2006;11:193–5.CrossRefPubMed
26.
Zurück zum Zitat Singh AK, Radhakrishnan N, Seth T, Mishra P, Mahapatra M, Pati H. Diamond Blackfan anemia: a tertiary care center experience. Mediterr J Hematol Infect Dis. 2013;5:e2013039.CrossRefPubMedPubMedCentral Singh AK, Radhakrishnan N, Seth T, Mishra P, Mahapatra M, Pati H. Diamond Blackfan anemia: a tertiary care center experience. Mediterr J Hematol Infect Dis. 2013;5:e2013039.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Pospisilova D, Cmejlova J, Ludikova B, Stary J, Cerna Z, Hak J, et al. The Czech national Diamond-Blackfan anemia registry: clinical data and ribosomal protein mutations update. Blood Cells Mol Dis. 2012;48:209–18.CrossRefPubMed Pospisilova D, Cmejlova J, Ludikova B, Stary J, Cerna Z, Hak J, et al. The Czech national Diamond-Blackfan anemia registry: clinical data and ribosomal protein mutations update. Blood Cells Mol Dis. 2012;48:209–18.CrossRefPubMed
28.
Zurück zum Zitat Smetanina NS, Mersiyanova IV, Kurnikova MA, Ovsyannikova GS, Hachatryan LA, Bobrynina VO, et al. Clinical and genomic heterogeneity of Diamond Blackfan anemia in the Russian Federation. Pediatr Blood Cancer. 2015;62:1597–600.CrossRefPubMedPubMedCentral Smetanina NS, Mersiyanova IV, Kurnikova MA, Ovsyannikova GS, Hachatryan LA, Bobrynina VO, et al. Clinical and genomic heterogeneity of Diamond Blackfan anemia in the Russian Federation. Pediatr Blood Cancer. 2015;62:1597–600.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Finlay JL, Shahidi NT, Horowitz S, Borcherding W, Hong R. Lymphocyte dysfunction in congenital hypoplastic anemia. J Clin Investig. 1982;70:619–26.CrossRefPubMedPubMedCentral Finlay JL, Shahidi NT, Horowitz S, Borcherding W, Hong R. Lymphocyte dysfunction in congenital hypoplastic anemia. J Clin Investig. 1982;70:619–26.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Khan S, Pereira J, Darbyshire PJ, Holding S, Dore PC, Sewell WA, et al. Do ribosomopathies explain some cases of common variable immunodeficiency? Clin Exp Immunol. 2011;163:96–103.CrossRefPubMedPubMedCentral Khan S, Pereira J, Darbyshire PJ, Holding S, Dore PC, Sewell WA, et al. Do ribosomopathies explain some cases of common variable immunodeficiency? Clin Exp Immunol. 2011;163:96–103.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Giri N, Alter BP, Penrose K, Falk RT, Pan Y, Savage SA, et al. Immune status of patients with inherited bone marrow failure syndromes. Am J Hematol. 2015;90:702–8.CrossRefPubMedPubMedCentral Giri N, Alter BP, Penrose K, Falk RT, Pan Y, Savage SA, et al. Immune status of patients with inherited bone marrow failure syndromes. Am J Hematol. 2015;90:702–8.CrossRefPubMedPubMedCentral
Metadaten
Titel
Clinical features, mutations and treatment of 104 patients of Diamond-Blackfan anemia in China: a single-center retrospective study
verfasst von
Yang Wan
Xiaojuan Chen
Wenbin An
Min Ruan
Jingliao Zhang
Lixian Chang
Ranran Zhang
Shuai Zhu
Yingchi Zhang
Wenyu Yang
Ye Guo
Weiping Yuan
Yao Zou
Yumei Chen
Xiaofan Zhu
Publikationsdatum
21.06.2016
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 4/2016
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-016-2044-9

Weitere Artikel der Ausgabe 4/2016

International Journal of Hematology 4/2016 Zur Ausgabe

Images in Hematology

Atypical amyloid deposits

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.